Published • loading... • Updated
Precede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate Cancer
Summary by The Hamilton Spectator
8 Articles
8 Articles
NiagaraFallsReview.ca+7 Reposted by 7 other sources
Precede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate Cancer
Baseline plasma profiling identified three molecular states previously characterized in tissue: androgen receptor (AR)-high/metabolic, stem/epithelial–mesenchymal transition (EMT), and AR-low/proliferative. The AR-high/metabolic group showed the most favorable outcome trends.Analysis of published gene sets corroborated these findings: higher stem-like and WNT signaling…
·Niagara Falls, Canada
Read Full ArticleCoverage Details
Total News Sources8
Leaning Left6Leaning Right2Center0Last UpdatedBias Distribution75% Left
Bias Distribution
- 75% of the sources lean Left
75% Left
L 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
